Article
Validation of TypeSeq2, a Next-Generation-Based Sequencing Assay for the Detection of 46 Human Papillomavirus Genotypes, at the US National Cancer Institute and Costa Rica Laboratories.
The Journal of infectious diseases - 20 Dec 2025
Sierra Mónica S, Coto Carolina, Porras Carolina, Herrero Rolando, Ugalde Daniela, Sauer Ashley N, Mora Daniela, Montes Claudia P, Schussler John, Hoffman Amanda C, Hicks Belynda, Ruggieri David, Cortes Bernal, Hildesheim Allan, Kreimer Aimée R, Wentzensen Nicolas, Dagnall Casey, Liu Danping
Abstract excerpt
BACKGROUND: Cervical cancer is caused by persistent infection with carcinogenic human papillomavirus (HPV) genotypes. Prophylactic HPV vaccines are highly efficacious in preventing the acquisition of HPV infection. HPV vaccine trials and epidemiologic studies based on virologic endpoints rely on valid and reproducible measurements of HPV. We evaluated the second version of TypeSeq (TS2), a next-generation,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.